Abstract
The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors, a set of three receptor sub-types encoded by distinct genes, function as lipid sensors to regulate a broad range of genes in many metabolically active tissues. Synthetic PPAR agonists have exhibited therapeutic benefits in treating diabetes and cardiovascular diseases. The discovery of PPAR-specific ligands has led to significant advancement in our understanding of the structure of these receptor proteins and the molecular mechanism of their ligand-dependent activation. Herein, we present both recent progress in the functional analysis of these orphan receptors and the confirmation of the PPARs as molecular targets for the development of new medicines to treat human metabolic disease.
Keywords: peroxisome proliferator, ppar, nuclear receptor, ppar agonists, ppar-specific
Current Medicinal Chemistry
Title: Recent Advances in Peroxisome Proliferator-Activated Receptor Science
Volume: 10 Issue: 4
Author(s): Barry G. Shearer and William J. Hoekstra
Affiliation:
Keywords: peroxisome proliferator, ppar, nuclear receptor, ppar agonists, ppar-specific
Abstract: The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors, a set of three receptor sub-types encoded by distinct genes, function as lipid sensors to regulate a broad range of genes in many metabolically active tissues. Synthetic PPAR agonists have exhibited therapeutic benefits in treating diabetes and cardiovascular diseases. The discovery of PPAR-specific ligands has led to significant advancement in our understanding of the structure of these receptor proteins and the molecular mechanism of their ligand-dependent activation. Herein, we present both recent progress in the functional analysis of these orphan receptors and the confirmation of the PPARs as molecular targets for the development of new medicines to treat human metabolic disease.
Export Options
About this article
Cite this article as:
Shearer G. Barry and Hoekstra J. William, Recent Advances in Peroxisome Proliferator-Activated Receptor Science, Current Medicinal Chemistry 2003; 10 (4) . https://dx.doi.org/10.2174/0929867033368295
DOI https://dx.doi.org/10.2174/0929867033368295 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Tumor Detection Using Machine Learning and Deep Learning: A
Review
Current Medical Imaging Folate Deficiency and Aberrant Expression of DNA Methyltransferase 1 were Associated with Cervical Cancerization
Current Pharmaceutical Design The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Targeting Strategies for Glucose Metabolic Pathways and T Cells in Colorectal Cancer
Current Cancer Drug Targets An Integrative “Omics” Approach, for Identification of Bona Fides PLK1 Associated Biomarker in Esophageal Adenocarcinoma
Current Cancer Drug Targets A Challenge for Medicinal Chemistry by the 17β-hydroxysteroid Dehydrogenase Superfamily: An Integrated Biological Function and Inhibition Study
Current Topics in Medicinal Chemistry Translational Research and Standardization in Optical Imaging
Current Molecular Imaging (Discontinued) Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Oxidative Stress Upregulates PDCD4 Expression in Patients with Gastric Cancer via miR-21
Current Pharmaceutical Design The Effects of the Endocrine Disruptors Dithiocarbamates on the Mammalian Ovary with Particular Regard to Mancozeb
Current Pharmaceutical Design IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes?
Current Women`s Health Reviews Microbiology of the Human Intestinal Tract and Approaches for Its Dietary Modulation
Current Pharmaceutical Design Smart Inulin-Based Polycationic Nanodevices for siRNA Delivery
Current Drug Delivery Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets Probiotics in Curing Allergic and Inflammatory Conditions - Research Progress and Futuristic Vision
Recent Patents on Inflammation & Allergy Drug Discovery Fragment-based Discovery of Potential Anticancer Lead: Computational and in vitro Studies
Current Computer-Aided Drug Design Surgery for Severe Obesity: Indications, Techniques, Mechanisms of Weight Loss and Diabetes Resolution
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)